摘要
目的 :比较罗通定与卡托普利治疗高血压的疗效和安全性。方法 :将 12 9例原发性高血压病人随机分为罗通定组 65例 (男性 4 2例 ,女性 2 3例 ,年龄 55a±s9a)用罗通定 30~ 90mg ,po ,tid ;卡托普利组 64例 (男性 39例 ,女性 2 5例 ,年龄 53a± 11a)用卡托普利 12 .5~ 50mg ,po ,bid或tid。 2组疗程均为 4wk。结果 :治疗 4wk后 ,2组血压下降差别均有非常显著意义 (P <0 .0 1) ;罗通定组的总有效率为 91% ,卡托普利组为 92 % ,2组疗效差别无显著意义 (P >0 .0 5)。罗通定与卡托普利均无严重不良反应 ,但卡托普利组有 2例因咳嗽频繁而停药。结论 :罗通定与卡托普利治疗原发性高血压均疗效好。
AIM: To compare the efficacy and safety of rotundine and captopril in treating essential hypertension (EH). METHODS: Patients with EH ( n=129) were randomly divided into 2 groups. Rotundine group (M42, F23; age 55 a± s 9 a) was treated with rotundine 30-90 mg(186 mg·d -1 ±90 mg·d -1 ), po ,tid for 4 wk. Captopril group (M39,F25;age 53 a±11 a) was treated with captopril 12.5-50 mg(92 mg·d -1 ±55 mg·d -1 ), po ,bid or tid for 4 wk. RESULTS: After 4 wk of therapy, both groups showed reduction of blood pressure ( P < 0.01). The total response rates of rotundine and captopril were 91% and 92% respectively ( P >0.05). The adverse reactions of 2 groups were mild. But medication had to be stopped on 2 patients in the captopril group because of frequent cough. CONCLUSION: Both rotundine and captopril are effective and safe in treating EH.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2001年第1期45-47,共3页
Chinese Journal of New Drugs and Clinical Remedies